PVI
ALXN

Pura Vida Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Pura Vida Investments’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-156,581
Closed -$23.9M – 304
2021
Q1 		$23.9M Buy
156,581
+32,685
+26% +$5.06M 0.68% 29
2020
Q4 		$19.4M Sell
123,896
-72,400
-37% -$9.3M 0.7% 33
2020
Q3 		$22.5M Sell
196,296
-8,400
-4% -$906K 1.16% 17
2020
Q2 		$23M Sell
204,696
-3,300
-2% -$350K 2.21% 11
2020
Q1 		$18.7M Buy
207,996
+120,806
+139% +$11.9M 2.22% 13
2019
Q4 		$9.43M Buy
87,190
+34,690
+66% +$3.71M 0.83% 43
2019
Q3 		$5.14M Buy
+52,500
New +$5.92M 0.88% 40
2019
Q1 		– Sell
-34,237
Closed -$3.33M – 132
2018
Q4 		$3.33M Buy
34,237
+19,113
+126% +$2.26M 0.67% 33
2018
Q3 		$2.1M Buy
15,124
+5,124
+51% +$643K 0.44% 62
2018
Q2 		$1.24M Sell
10,000
-35,000
-78% -$4.09M 0.5% 64
2018
Q1 		$5.02M Buy
45,000
+25,100
+126% +$3M 2.96% 9
2017
Q4 		$2.38M Sell
19,900
-4,000
-17% -$487K 1% 41
2017
Q3 		$3.35M Sell
23,900
-64,212
-73% -$8.72M 0.98% 41
2017
Q2 		$10.7M Buy
88,112
+20,612
+31% +$2.4M 4.26% 4
2017
Q1 		$8.18M Buy
+67,500
New +$8.7M 2.42% 11
2016
Q4 		– Sell
-66,375
Closed -$8.13M – 106
2016
Q3 		$8.13M Buy
66,375
+21,705
+49% +$2.79M 2.47% 8
2016
Q2 		$5.22M Buy
44,670
+8,670
+24% +$1.23M 2.22% 14
2016
Q1 		$5.01M Buy
36,000
+23,250
+182% +$3.41M 2.28% 12
2015
Q4 		$2.43M Buy
12,750
+250
+2% +$43.7K 1.03% 44
2015
Q3 		$1.96M Hold
12,500
– – 1.12% 38
2015
Q2 		$2.47M Buy
12,500
+2,500
+25% +$431K 1.26% 38
2015
Q1 		$1.73M Buy
10,000
+5,125
+105% +$928K 0.89% 41
2014
Q4 		$902K Buy
+4,875
New +$903K 0.33% 60

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Pura Vida Investments's ALXN Position: Q2 2021 in Review

Pura Vida Investments sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 156,581 shares — an estimated $23.9M sold.

Pura Vida Investments first reported a position in ALXN in Q4 2014 and held it in 23 quarters. The position peaked at $23.9M in Q1 2021. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Pura Vida Investments reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Pura Vida Investments sold 156,581 Alexion Pharmaceuticals shares in Q2 2021, an estimated $23.9M.
  • Pura Vida Investments first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 23 quarters.
  • Pura Vida Investments's Alexion Pharmaceuticals position peaked at $23.9M in Q1 2021.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Pura Vida Investments's 13F filing for Q2 2021, filed 16 Aug 2021.